Johnson & Johnson (NYSE: JNJ) is considering selling its stroke care unit for a potential valuation of $1 billion-plus, the Financial Times reports.
Why it matters: After spending some $30 billion on acquisitions to build its med tech portfolio in the last three years, J&J is taking out its pruning shears.
